Seeking Alpha

Idera Pharma updates on tilsotolimod

|About: Idera Pharmaceuticals,... (IDRA)|By: , SA News Editor

Ahead of its presentation at JPMorgan's Healthcare Conference, Idera on Thursday, Idera Pharmaceuticals (NASDAQ:IDRA) provides the following pipeline update:

Enrollment in Phase 3 ILLUMINATE 301 study comparing tilsotolimod + Bristol-Myers Squibb's Yervoy (ipilimumab) to Yervoy alone in PD-1 inhibitor-refractory metastatic melanoma patients should be completed this quarter with topline data expected in Q4/Q1 2021.

Preliminary response rate and safety data from Phase 2 ILLUMINATE 206 study of tilsotolimod + Yervoy and Opdivo (nivolumab) in solid tumors expected next quarter.

Final results from Phase 1/2 ILLUMINATE 204 study of tilsotolimod + Yervoy or Merck's Keytruda (pembrolizumab) in anti-PD-1-refractory metastatic melanoma patients should be available next quarter.


Try Seeking Alpha PREMIUM for unlimited analysis on IDRA